Senate confirms Stephen Hahn as FDA commissioner

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Senate Dec. 12 voted 72-18 to confirm Stephen Hahn as FDA commissioner.

Hahn, 59, is chief medical executive at MD Anderson Cancer Center and professor in the Department of Radiation Oncology.

On Dec. 3, members of the Senate Committee on Health Education Labor and Pensions voted 18-5 to confirm Hahn (The Cancer Letter, Dec. 6). The White House announced its intention to nominate Hahn Nov. 1 (The Cancer Letter, Sept. 6, Nov. 1).

In his Senate confirmation hearing Nov. 20, Hahn acknowledged that the rise in e-cigarette use among youths “is an important, urgent crisis in this country,” but made no specific pledges as Democratic and Republican Senate members pressed him on whether he would resist pressure from the administration and lobbying groups. (The Cancer Letter, Nov. 22).

Once sworn in, Hahn will become the 24th FDA commissioner, succeeding Scott Gottlieb.

Table of Contents

YOU MAY BE INTERESTED IN

Leadership is changing at The Wistar Institute and the Helen F. Graham Cancer Center & Research Institute in the months to come—but the leaders of the two institutions say that this will have little if any effect on the clinical-research collaboration that they have spent the past 15years building (The Cancer Letter, July 12, 2019). 
March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login